Browse CD1A

Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Membrane raft Single-pass type I membrane protein Endosome membrane Single-pass type I membrane protein Note=Subject to intracellular trafficking between the cell membrane and endosomes (PubMed:11231314). Localizes to cell surface lipid rafts (PubMed:18178838).
Domain PF07654 Immunoglobulin C1-set domain
PF16497 MHC-I family domain
Function

Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002475 antigen processing and presentation via MHC class Ib
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0048003 antigen processing and presentation of lipid antigen via MHC class Ib
GO:0048007 antigen processing and presentation, exogenous lipid antigen via MHC class Ib
Molecular Function GO:0003823 antigen binding
GO:0030881 beta-2-microglobulin binding
GO:0030882 lipid antigen binding
GO:0030883 endogenous lipid antigen binding
GO:0030884 exogenous lipid antigen binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0071723 lipopeptide binding
Cellular Component GO:0010008 endosome membrane
GO:0044440 endosomal part
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04530 Tight junction
hsa04640 Hematopoietic cell lineage
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD1A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16516282Vulvar Intraepithelial NeoplasiaPromote immunity (T cell function)Reduction in CD1a expression may reflect the inability of the host to mount an adequate immune response due to reduced antigen presentation in high grade VIN.
16917008Multiple myeloma(IgA, IgD, IgE, IgM, IgG)Promote immunityWe found that patient-derived MoDCs are phenotypically and functionally defective. Compared with their normal counterparts, patient-derived, mature MoDCs expressed significantly lower levels of CD1a, CD40, CD80, and HLA-DR and were poor at activating alloreactive T cells, presenting recall antigen, and activating autologous antigen- and myeloma-specific T cells.
Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5680.192
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4960.512
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6220.327
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5910.529
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3990.331
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.420.79
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4530.62
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1590.911
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8870.576
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1550.718
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0450.941
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8470.00485
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD1A
NameCD1a molecule
Aliases CD1A antigen, a polypeptide; CD1a antigen; FCB6; HTA1; R4; T-cell surface antigen T6/Leu-6; cluster of diffe ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD1A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD1A.
ID Name Drug Type Targets #Targets
DB00098Antithymocyte immunoglobulin (rabbit)BiotechCD1A, CD4, CD86, FCGR2B, ITGAL, ITGAV, ITGB1, ITGB3, MR19